Healthcare / Drug Manufacturers - Specialty & GenericBSE
$29.12
-0.02 (-0.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-69.6M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12.8B
P/E
58.2x
↑EV/EBITDA
38.2x
↑ROE
24.6%
↑Gross Margin
72.1%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-1.2%
FCF CAGR
—
FCF margin
-20.8%
FCF / Net income
-0.53x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $567.3M · net income $220.6M · FCF $-118.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $567.3M | $567.3M | $325.9M | $745.7M | $588.3M |
| Net Income | $220.6M | $220.6M | $95.8M | $185.4M | $44.1M |
| EBITDA | $333.2M | $333.2M | $169.4M | $222.1M | $65.3M |
| EPS | — | — | 0.22 | 0.42 | 0.66 |
| Gross Margin | 72.1% | 72.1% | 75.1% | 40.3% | 23.0% |
| Operating Margin | 44.6% | 44.6% | 29.8% | 23.3% | 6.0% |
| Net Margin | 38.9% | 38.9% | 29.4% | 24.9% | 7.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.07 | 0.05 | 0.20 |
| Current Ratio | 3.63 | 3.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-118.0M | $-118.0M | $51.8M | $-69.6M | $-13.2M |
| Returns | |||||
| ROE | 24.6% | 24.6% | 15.2% | 32.2% | 17.4% |
| Valuation | |||||
| P/E | 58.24 | 58.24 | 91.68 | 17.93 | 2.02 |
| EV/EBITDA | 38.24 | 38.24 | 51.36 | 14.54 | 1.53 |
| P/B | 14.19 | 14.19 | 13.97 | 5.72 | 0.35 |
| Growth & Yield | |||||
| Revenue Growth | 74.1% | 74.1% | -56.3% | 26.8% | — |
| EPS Growth | — | — | -47.6% | -35.9% | — |
| Dividend Yield | 0.0% | 0.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+119.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.22 → n/d
Residual
+119.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.